Directorate Change

RNS Number : 3948X

OKYO Pharma Limited

19 December 2019

 

DIRECTORATE CHANGE

OKYO Pharma Limited ("OKYO" or the "Company") is pleased to announces that Gregor MacRae has been appointed as a non-executive director of the company with immediate effect. Leopoldo Zambeletti is simultaneously standing down as a director of the Company with immediate effect.

Gregor is a business adviser, who specialises in taxation and cross border solutions. Presently, Gregor is the Senior Partner of Appledore Wealth Management LLP which is a London-based high net worth business advisory partnership. Previously, Gregor has been a director of an international trust company (Vistra UK Limited, formerly Chiltern Group Plc), which included holding the position of managing director of the taxation and private client groups.

Gregor holds a degree in Law from University of Birmingham (LLB Hons) and is a qualified Chartered Accountant (ICAEW).

Gregor will chair the Audit and Risk Committee of the Board (which also comprises Willy Simon) and will sit as a member of the Remuneration Committee (which also comprises Willy Simon as chairman).

Willy Simon, Chairman of OKYO, said "We are delighted that Gregor has joined the Board of OKYO.  His expertise will be of great value to us.  He is a great addition to the Board at a very important time for the group. I thank Leopoldo for his contribution to the Board and the Company and wish him well in his other interests". 

Gregor is also a director of B C Estate Limited and senior partner of Appledore Wealth Management LLP. Save as disclosed herein, there are no further details required to be disclosed pursuant to Listing Rule 9.6.13 in connection with Gregor's appointment.

About OKYO

OKYO Pharma Limited (LSE: OKYO) is a life sciences and biotechnology company admitted to listing on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the Main Market for listed securities of the London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain.

Enquiries:

OKYO Pharma Limited	Willy Simon	[phone]
Shore Capital  Limited (Broker)	Antonio Bossi David Coaten	[phone]

For further information, please visit the Company's website at www.okyopharma.com.

 

END

 

 

BOAZMMMZNRDGLZM